Seres Therapeutics (MCRB) Cash & Equivalents: 2015-2025
Historic Cash & Equivalents for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $47.6 million.
- Seres Therapeutics' Cash & Equivalents fell 28.71% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year decrease of 28.71%. This contributed to the annual value of $30.8 million for FY2024, which is 75.94% down from last year.
- Seres Therapeutics' Cash & Equivalents amounted to $47.6 million in Q3 2025, which was up 4.98% from $45.4 million recorded in Q2 2025.
- Seres Therapeutics' 5-year Cash & Equivalents high stood at $353.2 million for Q3 2021, and its period low was $30.8 million during Q4 2024.
- Its 3-year average for Cash & Equivalents is $95.8 million, with a median of $71.2 million in 2024.
- Per our database at Business Quant, Seres Therapeutics' Cash & Equivalents spiked by 396.84% in 2021 and then crashed by 75.94% in 2024.
- Seres Therapeutics' Cash & Equivalents (Quarterly) stood at $180.0 million in 2021, then dropped by 9.43% to $163.0 million in 2022, then fell by 21.51% to $128.0 million in 2023, then tumbled by 75.94% to $30.8 million in 2024, then dropped by 28.71% to $47.6 million in 2025.
- Its last three reported values are $47.6 million in Q3 2025, $45.4 million for Q2 2025, and $58.8 million during Q1 2025.